ViroPharma Sinks After FDA Denies Vancocin Exclusivity
By Marie Powers
Wednesday, April 11, 2012
Shares of ViroPharma Inc. were rocked Tuesday after the FDA informed the company that the supplemental new drug application (sNDA) for its antibiotic Vancocin (vancomycin hydrochloride), approved in December 2011, would not qualify for three additional years of exclusivity.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.